

Amoxapine – Drug Shortage

- The <u>drug shortage</u> of Teva's <u>amoxapine</u> is ongoing. Amoxapine has been unavailable for at least 90 days due to manufacturing delays from capacity constraints.
 - Per Teva, amoxapine is backordered until July 2020.
- Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Product Description	NDC #	Estimated Availability
Amoxapine tablets	25 mg: 0591-5713-01; 50 mg: 0591-5714-01; 100 mg: 0591-5715-01; 150 mg: 0591-5716-01	July 2020

 Other medications indicated to treat symptoms of depression such as tricyclic antidepressants (eg, <u>amitriptyline</u> and <u>imipramine</u>), selective serotonin reuptake inhibitors (eg, <u>citalopram</u>, and <u>fluoxetine</u>), selective serotonin and norepinephrine reuptake inhibitors (eg, <u>desvelanfaxine</u> and <u>duloxetine</u>) are currently available.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.